Stephen Headey
Stephen is an expert in fragment-based drug design (FBDD) based at RMIT University. Stephen has worked on a wide variety of drug targets including HIV integrase and reverse transcriptase. His current aim is to increase CRISPR efficiency for gene editing. To this end, he recently discovered and validated the first compound to reliably enhance CRISPR in vivo, a discovery which will double the rate at which transgenic animals can be created. Stephen is also an expert in protein NMR spectroscopy and has solved the structures of many biologically important proteins to provide insight into their structure-function relationships.
Abstracts this author is presenting:
